(MGRO) MustGrow Biologics - Ratings and Ratios

Exchange: V • Country: Canada • Currency: CAD • Type: Common Stock •

MGRO: Biopesticides, Biofertilizers, Soil Amendments, Biocontrols

MustGrow Biologics Corp. (V:MGRO) is an agricultural biotechnology company specializing in the development and commercialization of natural biological technologies derived from mustard seeds. The companys Biocontrol technology platform addresses soil-borne diseases and pests across various crops, including fruits and vegetables, while also targeting organic agriculture and home garden markets where glyphosate is banned. Additionally, the platform is used to suppress sprouting and treat diseases in storage and food preservation. The companys product portfolio includes TerraMG, a mustard-derived soil biopesticide, and TerraSante, an organic soil amendment and biofertility technology under development. Established in 2014 and headquartered in Saskatoon, Canada, MustGrow Biologics Corp. was formerly known as Duport Capital Ltd. before changing its name in March 2018.

Over the next three months, MustGrow Biologics Corp. (V:MGRO) is expected to face a challenging environment based on current technical and fundamental analysis. Technically, the stock is in a downtrend, with the last price of 1.15 sitting below the SMA20 (1.32) and SMA50 (1.39), indicating bearish momentum. The SMA200 at 1.22 further suggests that the stock is trading below its long-term average, reinforcing the downtrend. The ATR of 0.10 signals low volatility, which may limit significant price movements in either direction. On the fundamental side, the companys high P/B ratio of 18.70 and P/S ratio of 12.62 indicate a premium valuation relative to its book value and sales, which could pose a challenge for investors seeking value. The negative RoE of -7.27 highlights ongoing profitability challenges, which may weigh on investor sentiment. However, the companys focus on R&D and product development could position it for potential growth if it secures new partnerships or regulatory approvals. Overall, the stock is likely to remain under pressure in the near term, with limited upside potential unless driven by positive catalysts.

Additional Sources for MGRO Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

MGRO Stock Overview

Market Cap in USD 35m
Sector Basic Materials
Industry Agricultural Inputs
GiC Sub-Industry Fertilizers & Agricultural Chemicals
IPO / Inception

MGRO Stock Ratings

Growth Rating 40.8
Fundamental -30.0
Dividend Rating 0.0
Rel. Strength 14.2
Analysts -
Fair Price Momentum 1.01 CAD
Fair Price DCF -

MGRO Dividends

No Dividends Paid

MGRO Growth Ratios

Growth Correlation 3m -91.1%
Growth Correlation 12m 54.7%
Growth Correlation 5y -5.8%
CAGR 5y 28.70%
CAGR/Max DD 5y 0.33
Sharpe Ratio 12m -0.05
Alpha 4.33
Beta 0.892
Volatility 100.50%
Current Volume 13.5k
Average Volume 20d 6.9k
What is the price of MGRO stocks?
As of April 19, 2025, the stock is trading at CAD 1.13 with a total of 13,500 shares traded.
Over the past week, the price has changed by +4.63%, over one month by -6.61%, over three months by -22.07% and over the past year by +5.61%.
Is MustGrow Biologics a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, MustGrow Biologics (V:MGRO) is currently (April 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -29.96 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MGRO as of April 2025 is 1.01. This means that MGRO is currently overvalued and has a potential downside of -10.62%.
Is MGRO a buy, sell or hold?
MustGrow Biologics has no consensus analysts rating.
What are the forecast for MGRO stock price target?
According to ValueRays Forecast Model, MGRO MustGrow Biologics will be worth about 1.1 in April 2026. The stock is currently trading at 1.13. This means that the stock has a potential downside of -0.88%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 1.1 -0.9%